TOPIC:

Kristian Reich, Lars Erik Kristensen, Saxon D Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham

Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial

Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104
Leggi abstract | Scarica ppt
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Alessandro Zullo, Fabio Ferri, Martina Fiocchi, Emanuela Zagni

The CANOVA study real-world evidence of biologic treatments in moderate-severe psoriasis in italy: A gender perspective

Womens Health Rep (New Rochelle). 2022 May 2;3(1):450-457
Leggi abstract
A B Gottlieb, A Deodhar, I B Mcinnes, X Baraliakos, K Reich, S Schreiber, W Bao, K Marfo, H B Richards, L Pricop, A Shete, V Trivedi, D Keefe, C C Papavassilis, P Jagiello, P Papanastasiou, P J Mease, M Lebwohl

Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data

Acta Derm Venereol. 2022 Apr 27;102:adv00698
Leggi abstract | Scarica ppt